Brain tumor News
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!

Displaying Stories 41 to 60 of 6,391
Previous 20           Next 20




04/24/18 Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas        

 Carboxyamidotriazole Orotate is an experimental treatment, given orally.  It is made by Tactical Therapeutics.  Visit their website at 

http://www.tacticaltherapeutics.com/cto-overview/ for details on how it works.  Looks promising but too early to tell for sure.




04/24/18 Needed context absent from release on “less toxic way to treat brain tumors”        

 This brings up a very important point.  Every day we see an article claiming a breakthrough. Us old pros know it is just hyperbole - not really meant to be taken literally.  They are just trying to get their treatment noticed and if they told the truth in the headline, nobody would look at it.  But for the new people here, who are desperately looking for anything to help their loved one with a brain tumor, it is very dangerous. 

The website noted below digs into these stories and exposes the truth.  I like to think that is what we do here also with these editorials about the articles.  It gives perspective. Same with our online support groups: https://virtualtrials.com/lists.cfm   If you find something online that looks interesting for brain tumor patients, share it with one of the online groups.  




04/19/18 A Shock to the System: Tumor-Treating Fields Plus Temozolomide for Glioblastoma        

 Nothing we did not know before, but now this impressive journal has an article that says Optune should be the standard of care for GBMs.  This should help get insurance coverage for those few plans that still deny it.




04/18/18 Musella Foundation Copay assistance program is now closed to new and renewal patients        

 We just awarded our 1,000th grant (of $5,000 each) to a brain tumor  patient in need of help today!  

I know most people would rather donate to brain tumor research, but there is a huge need for this type of help also.   

We give you a choice when making a donation - you can pick where your donation goes!

 




04/18/18 Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.        

This study definitively proves what we already knew, that you do better if the entire tumor is removed. At a recent FDA advisory committee meeting I attended, the FDA said they did not believe that is the case.  Next time they will believe this study.

 




04/18/18 New Technology Crosses Blood-Brain Barrier To Fight Glioblastoma Cells Directly        

Interesting new drug - apparently did well in phase 1 testing.




04/18/18 First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1.        

 This is a big advance in brain tumor treatments. This new device allows the delivery of drugs to precisely where it is needed. Many clinical trials using convection enhanced delivery failed because the drug did not get to where it should have been.   Perhaps those trials should be redone using this system.  




04/17/18 Can all the money in the world beat cancer?        

 Maybe it could!  This person identified the collaboration between the Musella Foundation and Cancer Commons as one of the things he would fund if he raises all of that money!




04/17/18 Study Reports Possible Novel Method for Stopping Untreatable Pediatric Brain Cancer        

 It is way too early to say it stops these pediatric brain tumors but this is a new idea that hopefully will start human clinical trials soon!




04/14/18 WEALTH: All the money in the world: A couple whose child was diagnosed with a brain tumor is hoping an influx of funding will help find a cure.        

This man asked my opinon, and I told him: The Virtual Trial.  We are expanding our virtual trial concept, collaborating with other organizations, and now have a team of experts who can help find the best treatments, track the outcomes, and learn from every patient..  Go to virtualtrials.com/ask for details.

 




04/14/18 Musella Foundation Co-pay Assistance Program is about to close to new patients        

 Our copay assist program needs donations. I know most people like to donate to research only, and that is also badly needed. When you donate to the Musella Foundation (a https://virtualtrials.com/donate8.cfm ), we let you specify WHERE your donation will go, with 3 choices:

1. Brain tumor research only - 100% of your donation will go to research.  (we also have some specific funds you can donate to such as DIPG or Oligodendroglioma - on our website, click on donations, the Special Funds)

2. Copay assist program - 91% of your donation with go to a needy patient.  9% has to be used to cover the expense of running the program.

3. Anywhere it is needed.  This covers the foundations' expenses which allows us to provide our services, as well as educational resources. Anything left over is used for research. Never for copay.

 




04/12/18 CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (GBM) in China        

 This is a new approach . They are running trials in China for newly diagnosed and recurrent GBM patients.




04/12/18 Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.        

 This is a very important article.  Although a small sample, it opens the door to using a BRAF inhibitor for brain tumors that have the BRAF V-600 mutation. Note that this shouldn't be used in other mutations of BRAF, only the V-600 mutation. They found that using these drugs may actually speed up the tumor if they do not have the V-600 mutation.




04/06/18 The Musella Foundation For Brain Tumor Research & Information, Inc awarded a brain tumor research grant today!        

This is an interesting project.  This is  a preclinical experiment that may quickly lead to a human trial!  




04/06/18 Phase II clinical trial starts evaluating new drug for glioblastoma        

GDC-0084 (RG7666) which is a novel BBB-penetrating PI3K/mTOR inhibitor displaying a high brain-to-plasma ratio (1.9–3.3). It remarkably impedes the proliferation of five GBM cell lines and suppresses the growth of U-87 MG GBM xenografts through decreasing Akt phosphorylation 




04/04/18 A One-Two Combo Punch for Lung Cancer        

 This sounds pretty good. It also worked in a mouse model of glioblastoma, so they are going to start a trial of this combination for Glioblastoma patients.  Both parts of the combo are approved so they can be used off label now.




04/04/18 Apexigen to Recruit Children with Brain Tumors for Phase 1 Trial of Immunotherapy        

 This is a phase 1 trial, which means we do not yet have results but may sounds logical.




03/31/18 The Musella Foundation For Brain Tumor Research & Information, Inc awarded a brain tumor research grant today!        

 This is an important project because the drug being studied is approved for Lung Cancer. so if they find it useful for glioblastomas, it can immediately be used off label!




03/30/18 Optune Open House, Newton MA        

 This is a nice series of meetings for patients and caregivers who use (or are thinking of using) Optune.  




Displaying Stories 41 to 60 of 6391
Previous 20           Next 20


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites